Jeffrey Weinstein, MD
Infectious Disease · Dayton, OHNPI 1700878543
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,000 of the $6,307 with a category attached, or 95.1%. Incyte Corporation accounts for 95.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $6,000 and has fallen 98.6% since, to $82 in 2025.
Across 7 payments — averaging $901.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$6K
- Shionogi Inc$125
- Janssen Products, LP$100
- Gilead$82
Across 135 payments — averaging $5037.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$665K
- Amgen$15K
What the payments were for
- Speaking & faculty fees$6,00095%
- Food & beverage$2073%
- Education$1002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 1 | $6,000 |
| Shionogi Inc | 1 | $125 |
| Janssen Products, LP | 1 | $100 |
| Gilead | 4 | $82 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fetroja$125
How this compares
$6,307 in reported general payments places this provider in the 85th percentile of 308 infectious disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Dayton
- Steven BurdetteDayton$322K
- John CzachorDayton$15K
- Nathaniel RatnasamyFindlay$255K
- Melissa JenkinsCleveland$127K
- Grace McComseyCleveland$123K
- Steven GordonCleveland$78K
- Nicholas CongerWright Patterson Afb$76K
- Alan TaegeCleveland$76K
- Carlos MalvestuttoColumbus$70K
- Thomas FileAkron$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.